Lenacapavir is already approved for use as a treatment for multi-drug resistant HIV, costing around $42,250 for the first year of therapy in the United States. Clinical trials this year showed it ...
A new long-acting preventive HIV drug could reach the world’s poorest countries by the end of 2025 or early 2026, a global health official told Reuters on Tuesday. The ambition is to start ...
This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups ... in the field of PrEP, as drugs that prevent HIV are known. PrEP has been available ...